Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
Clinical trial NCT01192165 · COMPLETED
Trial details
- NCT number
- NCT01192165
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-09-14
- Primary completion
- 2013-10-07
- Enrollment
- 169
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.